These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37111326)

  • 1. A Systematic Review of Aminaphtone from Pathophysiology to Clinical Applications: Focus on New Rheumatological Acquisitions.
    Gotelli E; Soldano S; Hysa E; Pacini G; Pizzorni C; Paolino S; Cutolo M; Sulli A
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminaphtone Efficacy in Primary and Secondary Raynaud's Phenomenon: A Feasibility Study.
    Ruaro B; Pizzorni C; Paolino S; Alessandri E; Sulli A
    Front Pharmacol; 2019; 10():293. PubMed ID: 31019461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminaphtone in the control of gingival bleeding in children.
    Pereira de Godoy JM; Macedo Paizan ML
    Drug Des Devel Ther; 2014; 8():1331-4. PubMed ID: 25246774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M; Beckheinrich P; Haustein UF
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells.
    Salazar G; Bellocchi C; Todoerti K; Saporiti F; Piacentini L; Scorza R; Colombo GI
    Eur J Pharmacol; 2016 Jul; 782():59-69. PubMed ID: 27083548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-course gene expression data on the transcriptional effects of Aminaphtone on ECV304 endothelial cells.
    Salazar G; Bellocchi C; Todoerti K; Saporiti F; Piacentini L; Scorza R; Colombo GI
    Data Brief; 2016 Sep; 8():836-50. PubMed ID: 27508230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.
    Arefiev K; Fiorentino DF; Chung L
    Int J Rheumatol; 2011; 2011():201787. PubMed ID: 22121371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium channel blockers for primary and secondary Raynaud's phenomenon.
    Rirash F; Tingey PC; Harding SE; Maxwell LJ; Tanjong Ghogomu E; Wells GA; Tugwell P; Pope J
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD000467. PubMed ID: 29237099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aminaphtone on in vitro vascular permeability and capillary-like maintenance.
    Felice F; Belardinelli E; Frullini A; Santoni T; Imbalzano E; Di Stefano R
    Phlebology; 2018 Oct; 33(9):592-599. PubMed ID: 29059024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raynaud's Phenomenon with Focus on Systemic Sclerosis.
    Maciejewska M; Sikora M; Maciejewski C; Alda-Malicka R; Czuwara J; Rudnicka L
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.
    Fernández-Codina A; Cañas-Ruano E; Pope JE
    J Scleroderma Relat Disord; 2019 Jun; 4(2):102-110. PubMed ID: 35382396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raynaud's phenomenon-an update on diagnosis, classification and management.
    Pauling JD; Hughes M; Pope JE
    Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H; Anderson ME; Wilkinson J; Herrick AL
    Cochrane Database Syst Rev; 2014 Jan; (1):CD002069. PubMed ID: 24482037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis.
    Yamane K
    Intern Med; 1994 Oct; 33(10):579-82. PubMed ID: 7827371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.
    Knock GA; Terenghi G; Bunker CB; Bull HA; Dowd PM; Polak JM
    J Invest Dermatol; 1993 Jul; 101(1):73-8. PubMed ID: 8331298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.